MSH Capital Advisors LLC Takes Position in IQVIA Holdings Inc. $IQV

MSH Capital Advisors LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 3,050 shares of the medical research company’s stock, valued at approximately $589,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. International Assets Investment Management LLC purchased a new position in IQVIA in the 4th quarter worth approximately $27,000. Gilpin Wealth Management LLC purchased a new stake in IQVIA during the 4th quarter valued at approximately $27,000. CrossGen Wealth LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $28,000. Activest Wealth Management grew its stake in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares in the last quarter. Finally, Financial Freedom LLC bought a new stake in IQVIA in the 1st quarter valued at $25,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 4.0%

Shares of NYSE IQV opened at $249.62 on Thursday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36. The firm’s 50-day moving average price is $210.23 and its 200-day moving average price is $186.82. The stock has a market capitalization of $41.09 billion, a price-to-earnings ratio of 30.97, a P/E/G ratio of 2.04 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter last year, the business posted $2.81 earnings per share. The firm’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. BMO Capital Markets increased their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. HSBC reaffirmed a “buy” rating and issued a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. JPMorgan Chase & Co. increased their price target on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Finally, Robert W. Baird increased their target price on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $241.88.

Insider Buying and Selling

In other news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 12,913 shares of company stock worth $3,098,793 in the last 90 days. Company insiders own 1.70% of the company’s stock.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.